dactinomycin has been researched along with fenofibric acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Fujii, S; Furumoto, T; Goto, D; Ishimori, N; Kaneko, T; Kitabatake, A; Matsumoto, A; Sobel, BE; Sugawara, T; Watano, K | 1 |
1 review(s) available for dactinomycin and fenofibric acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for dactinomycin and fenofibric acid
| Article | Year |
|---|---|
Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.
Topics: 5' Flanking Region; Anticholesteremic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Dactinomycin; DNA; Endothelium, Vascular; Enzyme Inhibitors; Fenofibrate; Fibroblast Growth Factor 2; Flavonoids; Humans; Plasminogen Activator Inhibitor 1; Protein Synthesis Inhibitors; RNA, Messenger; Transcription, Genetic; Umbilical Veins | 2002 |